Loading...
Market
In how many countries will zanidatamab-hrii be approved for HER2+ BTC by the end of 2025?
2
Resolution / Starting Odds
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
Regulatory approval announcements from Jazz Pharmaceuticals or international health agencies
Story
FDA Approves Jazz's Zanidatamab for HER2+ Biliary Cancer with 52% Response Rate
Nov 21, 2024, 12:36 AM
The U.S. Food and Drug Administration (FDA) has approved a new drug, zanidatamab-hrii (Ziihera), developed by Jazz Pharmaceuticals, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). This approval marks a significant advancement in the treatment of this specific cancer type, with the drug showing a 52% response rate and a median duration of response of 14.9 months.
View original story
Similar markets
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 15 • 25%
More than 15 • 25%
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%
Less than 20 • 25%
20 to 40 • 25%
40 to 60 • 25%
More than 60 • 25%
Europe • 25%
Asia • 25%
North America • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%